Re-overcoming barriers in translating biomarkers to clinical practice

Expert Opinion on Medical Diagnostics

Volumn 4, Issue 2, 2010, Pages 103-112

  Staratschek Jox, Andrea ^a   Schultze, Joachim L ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Biomarker; Personalized medicine; Prediction; Prevention; Prognosis

Indexed keywords

2 (2 METHYL 2 PYRROLIDINYL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE; 3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; ALPHA INTERFERON; BCR ABL PROTEIN; BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMATINIB; MESSENGER RNA; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRASTUZUMAB; TUMOR MARKER;

ADVANCED CANCER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PREVENTION; CANCER RESEARCH; CANCER THERAPY; CELL CYCLE; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; COLON POLYP; COLONOSCOPY; COST EFFECTIVENESS ANALYSIS; DISEASE MARKER; DNA REPAIR; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FEASIBILITY STUDY; GENE AMPLIFICATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENOMICS; HEALTH CARE DELIVERY; HORMONAL THERAPY; HUMAN; LEUKEMIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; OUTCOME ASSESSMENT; PATIENT SELECTION; PHARMACODYNAMICS; PRECANCER; PREDICTION; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; VALIDATION PROCESS;

EID: 77953453510     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530051003657647     Document Type: Review

References (93)

1. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001;291(5507):1304-51
2. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;286(5439):531-7
3. Syvanen AC. Toward genome-wide SNP genotyping. Nat Genet 2005;37 (Suppl):S5-10
4. Hillier LW, Marth GT, Quinlan AR, et al. Whole-genome sequencing and variant discovery in C. elegans. Nat Methods 2008;5(2):183-8
5. Sawyers C. Targeted cancer therapy. Nature 2004;432(7015):294-7
6. Wong S, Witte ON. The BCR-ABL story: bench to bedside and back. Annu Rev Immunol 2004;22:247-306
7. Faratian D, Clyde RG, Crawford JW, Harrison DJ. Systems pathology-taking molecular pathology into a new dimension. Nat Rev Clin Oncol 2009;6(8):455-64
8. Amur S, Frueh FW, Lesko L, Shiew-Mei H. Intergration and use of biomarkers in drug development, regulation and clinical practice: a US regulatory perspective. Biomarkers Med 2008;2(3):305-11
9. Atkinson AJ, Colburn WA, DeGruttola VG, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69(3):89-95
10. Kim C, Taniyama Y, Paik S. Gene expression-based prognostic and predictive markers for breast cancer: a primer for practicing pathologists. Arch Pathol Lab Med 2009;133(6):855-9
11. Colburn WA, Lee JW. Biomarkers, validation and pharmacokinetic- pharmacodynamic modelling. Clin Pharmacokinet 2003;42(12):997-1022
12. Mutti A. Molecular diagnosis of lung cancer: an overview of recent developments. Acta Biomed 2008;79(Suppl 1):11-23
13. Pharoah PD, Antoniou AC, Easton DF, Ponder BA. Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med 2008;358(26):2796-803
14. Raz DJ, Jablons DM. Five-gene signature in non-small-cell lung cancer. N Engl J Med 2007;356(15):1582, author reply 3
15. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347(25):1999-2009
16. Merritt WM, Lin YG, Han LY, et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 2008;359(25):2641-50
17. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108(1):28-37
18. Modjtahedi H, Essapen S. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anticancer Drugs 2009;20(10):851-5
19. Sargent DJ, Conley BA, Allegra C, Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 2005;23(9):2020-7
20. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005;353(2):133-44
21. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366(9496):1527-37
22. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361(10):947-57
23. Kwak EL, Camidge DR, Clark J, et al. Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. J Clin Oncol 2009;27(15s):abstract 3509
24. Tan DS, Thomas GV, Garrett MD, et al. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. Cancer J 2009;15(5):406-20
25. Singer E. Personalized medicine prompts push to redesign clinical trials. Nat Med 2005;11(5):462
26. Jain KK. Challenges of drug discovery for personalized medicine. Curr Opin Mol Ther 2006;8(6):487-92
27. The biomarkers consortium. Available from: http://www. biomarkersconsortium.org/
28. Kuhlmann J. The applications of biomarkers in early clinical drug development to improve decision-making processes. Ernst Schering Res Found Workshop 2007(59):29-45
29. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415(6871):530-6
30. Bueno-de-Mesquita JM, van Harten WH, Retel VP, et al. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol 2007;8(12):1079-87
31. Glas AM, Floore A, Delahaye LJ, et al. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 2006;7:278
32. Esteban JB, Cronin J, Liu M, et al. Tumor gene expression and prognosis in breast cancer: multi-gene RT-PCR assay of paraffin-embedded tissue [abstract]. Prog Proc Am Soc Clin Oncol 2003;22:850
33. Cobleigh MB, Baker P, Cronin J, et al. Tumor gene expression predicts distant disease-free survival (DDFS) in breast cancer patients with 10 or more positive nodes: high throughout RT-PCR assay of paraffin-embedded tumor tissues [abstract]. Prog Proc Am Soc Clin Oncol 2003;22:850
34. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351(27):2817-26
35. Cardoso F, Van't Veer L, Rutgers E, et al. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 2008;26(5):729-35
36. Mook S, Van't Veer LJ, Rutgers EJ, et al. Individualization of therapy using Mammaprint: from development to the MINDACT Trial. Cancer Genomics Proteomics 2007;4(3):147-55
37. Sparano JA. TAILORx: trial assigning individualized options for treatment (Rx). Clin Breast Cancer 2006;7(4):347-50
38. Zujewski JA, Kamin L. Trial assessing individualized options for treatment for breast cancer: the TAILORx trial. Future Oncol 2008;4(5):603-10
39. Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002;8(8):816-24
40. Chen HY, Yu SL, Chen CH, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007;356(1):11-20
41. Garman KS, Acharya CR, Edelman E, et al. A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci USA 2008;105(49):19432-7
42. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3(8):711-5
43. Kummar S, Kinders R, Rubinstein L, et al. Compressing drug development timelines in oncology using phase '0' trials. Nat Rev Cancer 2007;7(2):131-9
44. US Food and Drug Administration. Guidance for Industry, Investigators, and Reviewers, Exploratory IND Studies. US Food and Drug Administration [online]. Available from: http://wwwfdagov/cder/guidance/7086fnlpdf 2006
45. DeGeorge JJ, Ahn CH, Andrews PA, et al. Regulatory considerations for preclinical development of anticancer drugs. Cancer Chemother Pharmacol 1998;41(3):173-85
46. Kinders R, Parchment RE, Ji J, et al. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice. Mol Interv 2007;7(6):325-34
47. Kummar S, Kinders R, Gutierrez ME, et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol 2009;27(16):2705-11
48. Staratschek-Jox A, Classen S, Gaarz A, et al. Blood-based transcriptomics: leukemias and beyond. Expert Rev Mol Diagn 2009;9(3):271-80
49. Yao Y, W HB, Morehouse C, et al. Development of potential pharmacodynamic and diagnosticmarkers for anti-IFN-alpha monoclonal antibody trials in systemic lupus erythematosus. Hum Genomics Proteomics 2009;2009, Article ID 374312
50. Classen S, Muth C, Debey-Pascher S, et al. Application of T cell-based transcriptomics to identify three candidate biomarkers for monitoring anti-TGFbR therapy. Pharmacogenet Genomics 2010;20(3):147-56
51. Dumur CI, Lyons-Weiler M, Sciulli C, et al. Interlaboratory performance of a microarray-based gene expression test to determine tissue of origin in poorly differentiated and undifferentiated cancers. J Mol Diagn 2008;10(1):67-77
52. Kohlmann A, Kipps TJ, Rassenti LZ, et al. An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the microarray innovations in leukemia study prephase. Br J Haematol 2008;142(5):802-7
53. Lieberman DA. Clinical practice. Screening for colorectal cancer. N Engl J Med 2009;361(12):1179-87
54. Naucler P, Ryd W, Tornberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007;357(16):1589-97
55. Tan EM, Zhang J. Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol Rev 2008;222:328-40
56. Zhang Y, Xuan J, de Los Reyes BG, et al. Network motif-based identification of breast cancer susceptibility genes. Conf Proc IEEE Eng Med Biol Soc 2008;2008:5696-9
57. Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. N Engl J Med 2009;361(2):170-7
58. Keller A, Leidinger P, Borries A, et al. miRNAs in lung cancer-studying complex fingerprints in patient's blood cells by microarray experiments. BMC Cancer 2009;9:353
59. Keller A, Leidinger P, Lange J, et al. Multiple sclerosis: microRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controls. PLoS One 2009;4(10):e7440
60. Schrohl AS, Wurtz S, Kohn E, et al. Banking of biological fluids for studies of disease-associated protein biomarkers. Mol Cell Proteomics 2008;7(10):2061-6
61. Vineis P, Riboli E. The EPIC study: an update. Recent Results Cancer Res 2009;181:63-70
62. Omenn GS. Chemoprevention of lung cancers: lessons from CARET, the beta-carotene and retinol efficacy trial, and prospects for the future. Eur J Cancer Prev 2007;16(3):184-91
63. Wichmann HE, Gieger C, Illig T. KORA-gen-resource for population genetics, controls and a broad spectrum of disease phenotypes. Gesundheitswesen 2005;67(Suppl 1):S26-30
64. Phillips C. Online resources for SNP analysis: a review and route map. Mol Biotechnol 2007;35(1):65-97
65. Lynch HT, Shaw MW, Magnuson CW, et al. Hereditary factors in cancer. Study of two large midwestern kindreds. Arch Intern Med 1966;117(2):206-12
66. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266(5182):66-71
67. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378(6559):789-92
68. Eng C, Hampel H, de la Chapelle A. Genetic testing for cancer predisposition. Annu Rev Med 2001;52:371-400
69. Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med 2008;359(20):2143-53
70. Suh Y, Vijg J. SNP discovery in associating genetic variation with human disease phenotypes. Mutat Res 2005;573(1-2):41-53
71. Imyanitov EN. Gene polymorphisms, apoptotic capacity and cancer risk. Hum Genet 2009;125(3):239-46
72. Frank SA. Genetic predisposition to cancer - insights from population genetics. Nat Rev Genet 2004;5(10):764-72
73. Kiyohara C, Yoshimasu K. Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: a meta-analysis. Int J Med Sci 2007;4(2):59-71
74. Wilding CS, Curwen GB, Tawn EJ, et al. Influence of polymorphisms at loci encoding DNA repair proteins on cancer susceptibility and G2 chromosomal radiosensitivity. Environ Mol Mutagen 2007;48(1):48-57
75. Vineis P. The relationship between polymorphisms of xenobiotic metabolizing enzymes and susceptibility to cancer. Toxicology 2002;181-182:457-62
76. Fan JB, Chee MS, Gunderson KL. Highly parallel genomic assays. Nat Rev Genet 2006;7(8):632-44
77. Tuma RS. Genome-wide association studies provoke debate and a new look at strategy. J Natl Cancer Inst 2009;101(15):1041-3
78. Shields PG, Harris CC. Cancer risk and low-penetrance susceptibility genes in gene-environment interactions. J Clin Oncol 2000;18(11):2309-15
79. Motsinger AA, Ritchie MD. Multifactor dimensionality reduction: an analysis strategy for modelling and detecting gene-gene interactions in human genetics and pharmacogenomics studies. Hum Genomics 2006;2(5):318-28
80. Hahn LW, Ritchie MD, Moore JH. Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics 2003;19(3):376-82
81. Mandrekar SJ, Grothey A, Goetz MP, Sargent DJ. Clinical trial designs for prospective validation of biomarkers. Am J Pharmacogenomics 2005;5(5):317-25
82. Sargent D, Allegra C. Issues in clinical trial design for tumor marker studies. Semin Oncol 2002;29(3):222-30
83. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007;131(1):18-43
84. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25(1):118-45
85. Eberhard DA, Giaccone G, Johnson BE. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol 2008;26(6):983-94
86. Debey S, Schoenbeck U, Hellmich M, et al. Comparison of different isolation techniques prior gene expression profiling of blood derived cells: impact on physiological responses, on overall expression and the role of different cell types. Pharmacogenomics J 2004;4(3):193-207
87. Debey S, Zander T, Brors B, et al. A highly standardized, robust, and cost-effective method for genome-wide transcriptome analysis of peripheral blood applicable to large-scale clinical trials. Genomics 2006;87(5):653-64
88. Cobb JP, Mindrinos MN, Miller-Graziano C, et al. Application of genome-wide expression analysis to human health and disease. Proc Natl Acad Sci USA 2005;102(13):4801-6
89. SPIDIA: Standardisation and improvement of generic pre-analytical tools and procedures for in-vitro diagnostics. Available from: http://www.spidia.eu/
90. Thomas RK, Nickerson E, Simons JF, et al. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med 2006;12(7):852-5
91. Delost MD, Miller WG, Chang GA, et al. Influence of credentials of clinical laboratory professionals on proficiency testing performance. Am J Clin Pathol 2009;132(4):550-4
92. Dowsett M, Hanna WM, Kockx M, et al. Standardization of HER2 testing: results of an international proficiency-testing ring study. Mod Pathol 2007;20(5):584-91
93. Franciotta D, Lolli F. Interlaboratory reproducibility of isoelectric focusing in oligoclonal band detection. Clin Chem 2007;53(8):1557-8